These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 23043035)

  • 21. Early beneficial effects of drug-eluting stents in vein grafts wane during long term follow-up: a case-control study.
    Pasceri V; Tarsia G; Niccoli G; Viceconte N; Porto I; Leone AM; Trani C; Speciale G; Lisanti P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1112-7. PubMed ID: 22422701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percutaneous Coronary Intervention of Saphenous Vein Graft.
    Redfors B; Généreux P; Witzenbichler B; McAndrew T; Diamond J; Huang X; Maehara A; Weisz G; Mehran R; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28495896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions.
    Pokala NR; Menon RV; Patel SM; Christopoulos G; Christakopoulos GE; Kotsia AP; Rangan BV; Roesle M; Abdullah S; Grodin J; Kumbhani DJ; Hastings J; Banerjee S; Brilakis ES
    Catheter Cardiovasc Interv; 2016 Jan; 87(1):34-40. PubMed ID: 26033073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
    Jeger RV; Schneiter S; Kaiser C; Bonetti PO; Brunner-La Rocca H; Handke M; Osswald S; Buser PT; Pfisterer ME;
    Cardiology; 2009; 112(1):49-55. PubMed ID: 18580059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions.
    Ybarra LF; Ribeiro HB; Pozetti AH; Campos CA; Esper RB; Lemos PA; Lopes AC; Kalil-Filho R; Ellis SG; Ribeiro EE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E856-63. PubMed ID: 23239630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
    Kaul U; Bangalore S; Seth A; Arambam P; Abhaichand RK; Patel TM; Banker D; Abhyankar A; Mullasari AS; Shah S; Jain R; Kumar PR; Bahuleyan CG;
    N Engl J Med; 2015 Oct; 373(18):1709-19. PubMed ID: 26466202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
    Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Holper EM; Haagen D; Saeed B; Iturbe JM; Shunk K; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
    JACC Cardiovasc Interv; 2009 Sep; 2(9):855-60. PubMed ID: 19778774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era.
    Pucelikova T; Mehran R; Kirtane AJ; Kim YH; Fahy M; Weisz G; Lansky AJ; Moussa I; Gray WA; Collins MB; Kodali SK; Stone GW; Moses JW; Leon MB; Dangas G
    Am J Cardiol; 2008 Jan; 101(1):63-8. PubMed ID: 18157967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
    Brilakis ES; O'Donnell CI; Penny W; Armstrong EJ; Tsai T; Maddox TM; Plomondon ME; Banerjee S; Rao SV; Garcia S; Nallamothu B; Shunk KA; Mavromatis K; Grunwald GK; Bhatt DL
    JACC Cardiovasc Interv; 2016 May; 9(9):884-93. PubMed ID: 27085582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optical coherence tomography analysis of the stenting of saphenous vein graft (SOS) Xience V Study: use of the everolimus-eluting stent in saphenous vein graft lesions.
    Papayannis AC; Michael TT; Yangirova D; Abdel-Karim AR; Kohlhaas J; Mahmood A; Addo T; Haagen D; Makke L; Roesle M; Rangan B; Banerjee S; Brilakis ES
    J Invasive Cardiol; 2012 Aug; 24(8):390-4. PubMed ID: 22865309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Haagen D; Saeed B; Gadiparthi C; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    J Am Coll Cardiol; 2009 Mar; 53(11):919-28. PubMed ID: 19281920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions.
    Assali A; Raz Y; Vaknin-Assa H; Ben-Dor I; Brosh D; Teplitsky I; Fuchs S; Kornowski R
    EuroIntervention; 2008 May; 4(1):108-14. PubMed ID: 19112787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques.
    Al-Lamee R; Ielasi A; Latib A; Godino C; Ferraro M; Arioli F; Mussardo M; Piraino D; Figini F; Carlino M; Montorfano M; Chieffo A; Colombo A
    Am J Cardiol; 2010 Dec; 106(12):1721-7. PubMed ID: 21126616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
    J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion.
    Brodie BR; VerSteeg DS; Brodie MM; Hansen C; Richter SJ; Stuckey TD; Gupta N; Pulsipher M; Downey W
    Catheter Cardiovasc Interv; 2005 Aug; 65(4):504-9. PubMed ID: 15988742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.